Synapse - Robert Motzer

Results (1243)

STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)

Meeting Abstract

Choueiri, T. K.; Bedke, J.; Karam, J. A.; McKay, R. R.; Motzer, R. J.; Pal, S. M.; Suárez, C.; Uzzo, R.; Liu, H.; Burgents, J. E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations

Meeting Abstract

Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clinical and immunogenomic outcomes of consolidative cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint blockade

Meeting Abstract

Reese, S. W.; Jiang, H.; Kuo, F.; Wu, C. Y.; Vuong, L.; Mascareno, E.; Oparanozie, A.; Motzer, R. J.; Voss, M. H.; Reznik, E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk

Meeting Abstract

Powles, T.; Motzer, R. J.; Albiges, L.; Suárez, C.; Schutz, F. A. B.; Heng, D. Y. C.; Chevreau, C.; Kanesvaran, R.; Gurney, H.; Wang, F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101

Meeting Abstract

Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Uemura, H.; Oya, M.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Huang, B; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC)

Meeting Abstract

Choueiri, T. K.; Motzer, R. J.; Powles, T.; Burotto, M.; Apolo, A. B.; Escudier, B.; Tomita, Y.; McDermott, D. F.; Braun, D. A.; Han, C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Correlating HLA variants and the emergence of immune-related adverse events (irAEs) from ipilimumab/nivolumab (I/N) in patients (pts) treated on CheckMate 214

Meeting Abstract

Voss, M. H.; Shah, N. J.; Kalvin, H. L.; Lihm, J.; Li, H.; Kotecha, R. R.; Jarchum, I.; Vemula, S. V.; Gupta, S.; Motzer, R. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial

Meeting Abstract

Burotto, M.; Powles, T.; Escudier, B.; Apolo, A. B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Porta, C.; Barrios, C. H.; Richardet, M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era

Journal Article

Shah, N. J.; Sura, S. D.; Shinde, R.; Shi, J.; Singhal, P. K.; Robert, N. J.; Vogelzang, N. J.; Perini, R. F.; Motzer, R. J.
European Urology Open Science (2023)

Fulltext@MSK | Save